UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.12.24

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.12.24 Stock

DE000HC49PW5

Market Closed - BOERSE MUENCHEN 15:40:17 2024-06-14 EDT
9.33 ^EUR	+3.09%

Current month	+28.51%
1 month	+71.82%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/18.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	06-14	MT
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress	06-14	BU
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing	06-13	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing	06-13	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-14	9.33	+3.09%
24-06-13	9.05	+3.31%
24-06-12	8.76	-6.71%
24-06-11	9.39	-1.68%
24-06-10	9.55	-0.31%

Real-time BOERSE MUENCHEN

Last update June 14, 2024 at 03:40 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HC49PW
ISIN	DE000HC49PW5
Date issued	2023-02-20
Strike	400 $
Maturity	2024-12-18 (185 Days)
Parity	10 : 1
Emission price	2.55 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	9.59 €
Lowest since issue	2.09 €
Delta	0.87x
Omega	4.244
Premium	3.76x
Gearing	4.87x
Moneyness	1.202
Difference Strike	-80.73 $
Difference Strike %	-20.18%
Spread	0.04 €
Spread %	0.43%
Theoretical value	9.220
Implied Volatility	28.49 %
Total Loss Probability	17.39 %
Intrinsic value	7.541
Present value	1.679
Break even	498.71 €
Theta	-0.07x
Vega	0.07x
Rho	0.15x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

480.7 USD

Average target price

463.4 USD

Spread / Average Target

-3.60%

Consensus